# Ticagrelor

## Brilinta 90mg

| TAH Drug Code      | [OBRI](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OBRI)                                                                                                                                                                                                                                                                                 |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Prevention of atherothrombotic events in patients w/ acute coronary syndromes (ACS) [unstable angina, non-ST elevation MI (NSTEMI) or ST elevation MI (STEMI)] including patients managed medically & managed w/ percutaneous coronary intervention (PCI) or CABG co-administered w/ acetylsalicylic acid (ASA).                                     |
| Dosing             | Acute coronary heart disease: loading dose as 180mg and followed by 90mg BID for 12 months. Patient with MI history combined with high risk of arterial thrombosis, needed an extended treatment: 60mg BID. 對於曾接受經皮冠狀動脈介入治療(PCI)且出血風險增加的ACS病人,可考慮在3個月後停用Aspirin,在此情況,Brilinta作為單一抗血小板治療應持續9個月。 |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                             |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                        |
| Contraindications  | Active pathological bleeding, history of intracranial haemorrhage, moderate to severe hepatic impairment, co-administration w/ strong CYP3A4 inhibitors.                                                                                                                                                                                             |
| Adverse Effects    | Dyspnoea, epistaxis, GI haemorrhage, subcutaneous or dermal bleeding, bruising, procedural site haemorrhage.                                                                                                                                                                                                                                         |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Risk                                                                                                                                                                                                                                                                                                   |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                         |
| More Info          | [UpToDate](https://www.uptodate.com/contents/ticagrelor-drug-information)                                                                                                                                                                                                                                                                            |

